Chemoimmunotherapy as long-term maintenance therapy for cancer

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 563-565

  Egilmez, Nejat K ^a   Harden, Jamie L ^a   Rowswell Turner, Rachael B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chemoimmunotherapy; Chronic treatment; Immune regulation; Interleukin 12; Spontaneous tumors

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DOSE SEQUENCE; HUMAN; IMMUNOCHEMOTHERAPY; IMMUNOREGULATION; LONG TERM CARE; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SUPPRESSOR CELL; T CELL DEPLETION; TUMOR DRAINING LYMPH NODE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886944257     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19369     Document Type: Article

References (10)

1. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117; http://dx.doi.org/10.1146/annurev.immunol.021908.132544
2. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256-61; http://dx.doi.org/10.1158/1078-0432.CCR-07-0892
3. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011; 241:104-18; http://dx.doi.org/10.1111/j.1600-065X.2011.01007.x
4. Hill HC, Conway TF, Jr., Sabel MS, Jong YS, Mathiowitz E, Bankert RB, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62:7254-63
5. Nair RE, Kilinc MO, Jones SA, Egilmez NK. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol 2006; 176:7325-34
6. Harden JL, Gu T, Kilinc MO, Rowswell-Turner RB, Virtuoso LP, Egilmez NK. Dichotomous effects of IFN-c on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. J Immunol 2011; 187:126-32; http://dx.doi.org/10.4049/jimmunol.1100168
7. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-36; http://dx.doi.org/10.1182/blood-2005-07-2737
8. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65:8059-64; http://dx.doi.org/10.1158/0008-5472.CAN-05-1797
9. Rowswell-Turner RB, Harden JL, Nair RE, Gu T, Kilinc MO, Egilmez NK. Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation. J Immunol 2011; 187:4109-18; http://dx.doi.org/10.4049/jimmunol.1101136
10. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity